The Genetics of Deafness
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genetic Testing for Non-Cancerous Inheritable Diseases
Genetic Testing for Non-Cancerous Inheritable Diseases Policy Number: Original Effective Date: MM.02.009 03/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/30/2016 Section: Medicine Place(s) of Service: Outpatient I. Description A genetic test is the analysis of human DNA, RNA, chromosomes, proteins, or certain metabolites in order to detect alterations related to an inheritable disorder. This can be accomplished by directly examining the DNA or RNA that makes up a gene (direct testing), looking at markers co-inherited with a disease-causing gene (linkage testing), assaying certain metabolites (biochemical testing), or examining the chromosomes (cytogenetic testing). Genetic tests are conducted for a number of purposes, including predicting disease risk, newborn screening, determining clinical management, identifying carriers, and establishing prenatal or clinical diagnoses or prognoses in individuals, families, or populations. Expanded Carrier Screening The American College of Medical Genetics (ACMG ) defines expanded panels as those that use next- generation sequencing to screen for mutations in many genes, as opposed to gene-by-gene screening (e.g., ethnic-specific screening or panethnic testing for cystic fibrosis). An ACMG position statement states that although commercial laboratories offer expanded carrier screening panels, there has been no professional guidance as to which disease genes and mutations to include. This policy does not address oncology-related genetic testing or pre-implantation genetic diagnosis (PGD). II. Criteria/Guidelines Note: For familial assessments, unless otherwise specified, family will be considered: first-, second- and third- degree relatives on the same side of the family. The maternal and paternal sides should be considered independently. -
Benefits of Exome Sequencing in Children with Suspected Isolated
G C A T T A C G G C A T genes Article Benefits of Exome Sequencing in Children with Suspected Isolated Hearing Loss Roxane Van Heurck 1, Maria Teresa Carminho-Rodrigues 1, Emmanuelle Ranza 1, Caterina Stafuzza 2, Lina Quteineh 1, Corinne Gehrig 1, Eva Hammar 1, Michel Guipponi 1, Marc Abramowicz 1, Pascal Senn 2 , Nils Guinand 2, Helene Cao-Van 2 and Ariane Paoloni-Giacobino 1,* 1 Division of Genetic Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland; [email protected] (R.V.H.); [email protected] (M.T.C.-R.); [email protected] (E.R.); [email protected] (L.Q.); [email protected] (C.G.); [email protected] (E.H.); [email protected] (M.G.); [email protected] (M.A.) 2 Ear-Nose-Throat/Head and Neck Surgery Division, Geneva University Hospitals, 1205 Geneva, Switzerland; [email protected] (C.S.); [email protected] (P.S.); [email protected] (N.G.); [email protected] (H.C.-V.) * Correspondence: [email protected] Abstract: Purpose: Hearing loss is characterized by an extensive genetic heterogeneity and remains a common disorder in children. Molecular diagnosis is of particular benefit in children, and permits the early identification of clinically-unrecognized hearing loss syndromes, which permits effective clinical management and follow-up, including genetic counselling. Methods: We performed whole-exome Citation: Van Heurck, R.; sequencing with the analysis of a panel of 189 genes associated with hearing loss in a prospective Carminho-Rodrigues, M.T.; Ranza, E.; cohort of 61 children and 9 adults presenting mainly with isolated hearing loss. -
Dissertationes Medicinae Universitatis Tartuensis 178
DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS 178 DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS 178 RITA TEEK The genetic causes of early onset hearing loss in Estonian children Department of Paediatrics, University of Tartu, Tartu, Estonia Dissertation is accepted for commencement of the degree of Doctor of Medical Sciences on September 22, 2010 by the Council of the Faculty of Medicine, University of Tartu, Estonia. Supervisors: Professor Katrin Õunap, MD, PhD, Department of Paediatrics, University of Tartu, Tartu, Estonia The Late Professor Mart Kull, MD, PhD, Department of Oto-Rhino-Laryngology, University of Tartu, Tartu, Estonia (2005–2008) Reviewers: Assistant Professor Gunnar Tasa, MD, PhD, Department of General and Molecular Pathology, University of Tartu, Tartu, Estonia Assistant Professor Oivi Uibo, MD, PhD, Department of Paediatrics, University of Tartu, Tartu, Estonia Opponent: Professor Lisbeth Tranebjærg, MD, PhD, Department of Audiology, H:S Bispebjerg Hospital, and Wilhelm Johannsen Centre of Functional Genomics Institute of Cellular and Molecular Medicine, ICMM, University of Copenhagen, The Panum Institute, Denmark Commencement: November 24, 2010 ISSN 1024–395x ISBN 978–9949–19–478–0 (trükis) ISBN 978–9949–19–479–7 (PDF) Autoriõigus: Rita Teek, 2010 Tartu Ülikooli Kirjastus www.tyk.ee Tellimuse nr. 570 To my patients and their families CONTENTS LIST OF ORIGINAL PUBLICATIONS ...................................................... 9 ABBREVIATIONS OF HEARING LOSS STUDY GROUPS AND PATIENTS .................................................................................................... -
Hearing Screening Training Manual REVISED 12/2018
Hearing Screening Training Manual REVISED 12/2018 Minnesota Department of Health (MDH) Community and Family Health Division Maternal and Child Health Section 1 2 For more information, contact Minnesota Department of Health Maternal Child Health Section 85 E 7th Place St. Paul, MN 55164-0882 651-201-3760 [email protected] www.health.state.mn.us Upon request, this material will be made available in an alternative format such as large print, Braille or audio recording. 3 Revisions made to this manual are based on: Guidelines for Hearing Screening After the Newborn Period to Kindergarten Age http://www.improveehdi.org/mn/library/files/afternewbornperiodguidelines.pdf American Academy of Audiology, Childhood Screening Guidelines http://www.cdc.gov/ncbddd/hearingloss/documents/AAA_Childhood%20Hearing%2 0Guidelines_2011.pdf American Academy of Pediatrics (AAP), Hearing Assessment in Children: Recommendations Beyond Neonatal Screening http://pediatrics.aappublications.org/content/124/4/1252 4 Contents Introduction .................................................................................................................... 7 Audience ..................................................................................................................... 7 Purpose ....................................................................................................................... 7 Overview of hearing and hearing loss ............................................................................ 9 Sound, hearing, and hearing -
Genes in Eyecare Geneseyedoc 3 W.M
Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease. -
Preconception Carrier Screening
Focusing on Personalised Medicine PRECONCEPTION CARRIER SCREENING Preconception carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Our Inherited Disease Panel tests over 300 genes associated with more than 700 unique commonly inherited diseases, including common forms of inherited deafness, blindness, heart disease, Parkinson’s disease, immunodeficiency, and various ataxias, anaemias, and treatable metabolic syndromes. The assay has been developed in conjunction with clinical molecular geneticists, and includeds genes listed in the NIH Genetic Test Registry. For a full list of genes and disorders covered, please see the reverse of this brochure. Why have Preconception Carrier Screening? Carrier screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or use donor gametes. Screening also allows couples to consider prenatal diagnosis and pregnancy management options in the event of an affected fetus. Whilst individually each disease tested is rare, around 25% of people will carry at least one abnormal mutation. These disorders are usually autosomal recessive, which means that a child must inherit a defective gene from each parent to have the disease. For autosomal recessive conditions, if a person is a carrier of the disease, they have one defective copy of the gene and one normal copy and typically don’t have any symptoms of the disease. -
Vestibular Neuritis, Labyrinthitis, and a Few Comments Regarding Sudden Sensorineural Hearing Loss Marcello Cherchi
Vestibular neuritis, labyrinthitis, and a few comments regarding sudden sensorineural hearing loss Marcello Cherchi §1: What are these diseases, how are they related, and what is their cause? §1.1: What is vestibular neuritis? Vestibular neuritis, also called vestibular neuronitis, was originally described by Margaret Ruth Dix and Charles Skinner Hallpike in 1952 (Dix and Hallpike 1952). It is currently suspected to be an inflammatory-mediated insult (damage) to the balance-related nerve (vestibular nerve) between the ear and the brain that manifests with abrupt-onset, severe dizziness that lasts days to weeks, and occasionally recurs. Although vestibular neuritis is usually regarded as a process affecting the vestibular nerve itself, damage restricted to the vestibule (balance components of the inner ear) would manifest clinically in a similar way, and might be termed “vestibulitis,” although that term is seldom applied (Izraeli, Rachmel et al. 1989). Thus, distinguishing between “vestibular neuritis” (inflammation of the vestibular nerve) and “vestibulitis” (inflammation of the balance-related components of the inner ear) would be difficult. §1.2: What is labyrinthitis? Labyrinthitis is currently suspected to be due to an inflammatory-mediated insult (damage) to both the “hearing component” (the cochlea) and the “balance component” (the semicircular canals and otolith organs) of the inner ear (labyrinth) itself. Labyrinthitis is sometimes also termed “vertigo with sudden hearing loss” (Pogson, Taylor et al. 2016, Kim, Choi et al. 2018) – and we will discuss sudden hearing loss further in a moment. Labyrinthitis usually manifests with severe dizziness (similar to vestibular neuritis) accompanied by ear symptoms on one side (typically hearing loss and tinnitus). -
Sudden Bilateral Simultaneous Deafness with Vertigo As a Sole Manifestation of Vertebrobasilar Insufficiency H Lee, H a Yi, R W Baloh
539 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.4.539 on 1 April 2003. Downloaded from SHORT REPORT Sudden bilateral simultaneous deafness with vertigo as a sole manifestation of vertebrobasilar insufficiency H Lee, H A Yi, R W Baloh ............................................................................................................................. J Neurol Neurosurg Psychiatry 2003;74:539–541 CASE REPORT A 68 year old woman presented with bilateral sudden A 68 year old woman with long standing non-insulin depend- simultaneous hearing loss and transient spontaneous ent diabetes mellitus and hypertension suddenly developed vertigo as a sole manifestation of vertebrobasilar vertigo, vomiting, and bilateral tinnitus. Five minutes later, insufficiency. Extensive investigation to exclude other she noticed bilateral hearing loss. She had difficulty hearing causes was unremarkable. Magnetic resonance imaging her husband speak. She did not have dysarthria, numbness, of the brain, including diffusion images, showed no abnor- weakness, visual distortion, or incoordination. The hearing malities. A magnetic resonance angiogram showed severe loss persisted, but vertigo resolved over a few hours. Two days stenosis of the middle third of the basilar artery. A pure previously, she had had two episodes of transient vertigo and tone audiogram showed moderate sensorineural-type hearing loss involving the left ear that lasted no more than a hearing loss bilaterally. The localisation and mechanism of few minutes without any accompanying neurological symp- an isolated cochleovestibular dysfunction are discussed. toms. The patient had no previous history of hearing difficulty. There was no prior history of temporal bone fracture, menin- gitis, autoimmune disease, or exposure to ototoxic drugs. On admission, she had persistent bilateral hearing loss and ertebrobasilar insufficiency (VBI) can cause sudden non-specific dizziness with lightheadedness. -
Central Auditory Function Evaluation to Diagnose Central Auditory Processing Disorder Product Applicability
bmchp.org | 888-566-0008 wellsense.org | 877-957-1300 Medical Policy Central Auditory Function Evaluation to Diagnose Central Auditory Processing Disorder Policy Number: OCA 3.82 Version Number: 17 Version Effective Date: 01/01/21 + Product Applicability All Plan Products Well Sense Health Plan ∆ Boston Medical Center HealthNet Plan ∆ Well Sense Health Plan MassHealth ACO MassHealth MCO Qualified Health Plans/ConnectorCare/Employer Choice Direct Senior Care Options Notes: + Disclaimer and audit information is located at the end of this document. ∆ As required by state regulations and/or benefit coverage, different Plan definitions are specified for BMC HealthNet Plan products and Well Sense Health Plan products. See the applicable Definitions section for the Plan member. Policy Summary The evaluation of central auditory functioning to diagnose central auditory processing disorder (CAPD) is considered medically necessary for an adult or pediatric member when applicable Plan criteria are met. The evaluation is medically necessary when it is not part of a member’s individualized education plan (IEP) when one is appropriate for the member, it is a covered benefit for the member, and the Plan’s medical criteria are met (as specified in the Medical Policy Statement section of this Plan policy). Prior authorization is required for Plan covered services. See the member’s applicable benefit document available at www.bmchp.org for a member enrolled in a BMC HealthNet Plan product or Central Auditory Function Evaluation to Diagnose Central Auditory Processing Disorder + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. -
Diseases of the Digestive System (KOO-K93)
CHAPTER XI Diseases of the digestive system (KOO-K93) Diseases of oral cavity, salivary glands and jaws (KOO-K14) lijell Diseases of pulp and periapical tissues 1m Dentofacial anomalies [including malocclusion] Excludes: hemifacial atrophy or hypertrophy (Q67.4) K07 .0 Major anomalies of jaw size Hyperplasia, hypoplasia: • mandibular • maxillary Macrognathism (mandibular)(maxillary) Micrognathism (mandibular)( maxillary) Excludes: acromegaly (E22.0) Robin's syndrome (087.07) K07 .1 Anomalies of jaw-cranial base relationship Asymmetry of jaw Prognathism (mandibular)( maxillary) Retrognathism (mandibular)(maxillary) K07.2 Anomalies of dental arch relationship Cross bite (anterior)(posterior) Dis to-occlusion Mesio-occlusion Midline deviation of dental arch Openbite (anterior )(posterior) Overbite (excessive): • deep • horizontal • vertical Overjet Posterior lingual occlusion of mandibular teeth 289 ICO-N A K07.3 Anomalies of tooth position Crowding Diastema Displacement of tooth or teeth Rotation Spacing, abnormal Transposition Impacted or embedded teeth with abnormal position of such teeth or adjacent teeth K07.4 Malocclusion, unspecified K07.5 Dentofacial functional abnormalities Abnormal jaw closure Malocclusion due to: • abnormal swallowing • mouth breathing • tongue, lip or finger habits K07.6 Temporomandibular joint disorders Costen's complex or syndrome Derangement of temporomandibular joint Snapping jaw Temporomandibular joint-pain-dysfunction syndrome Excludes: current temporomandibular joint: • dislocation (S03.0) • strain (S03.4) K07.8 Other dentofacial anomalies K07.9 Dentofacial anomaly, unspecified 1m Stomatitis and related lesions K12.0 Recurrent oral aphthae Aphthous stomatitis (major)(minor) Bednar's aphthae Periadenitis mucosa necrotica recurrens Recurrent aphthous ulcer Stomatitis herpetiformis 290 DISEASES OF THE DIGESTIVE SYSTEM Diseases of oesophagus, stomach and duodenum (K20-K31) Ill Oesophagitis Abscess of oesophagus Oesophagitis: • NOS • chemical • peptic Use additional external cause code (Chapter XX), if desired, to identify cause. -
The Pathological Consequences of Impaired Genome Integrity in Humans; Disorders of the DNA Replication Machinery
The pathological consequences of impaired genome integrity in humans; disorders of the DNA replication machinery Article (Accepted Version) O'Driscoll, Mark (2017) The pathological consequences of impaired genome integrity in humans; disorders of the DNA replication machinery. Journal of Pathology, 241 (2). pp. 192-207. ISSN 0022-3417 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/65956/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version. Copyright and reuse: Sussex Research Online is a digital repository of the research output of the University. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available. Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. http://sro.sussex.ac.uk The pathological consequences of impaired genome integrity in humans; disorders of the DNA replication machinery. -
2021 Code Changes Reference Guide
Boston University Medical Group 2021 CPT Code Changes Reference Guide Page 1 of 51 Background Current Procedural Terminology (CPT) was created by the American Medical Association (AMA) in 1966. It is designed to be a means of effective and dependable communication among physicians, patients, and third-party payers. CPT provides a uniform coding scheme that accurately describes medical, surgical, and diagnostic services. CPT is used for public and private reimbursement systems; development of guidelines for medical care review; as a basis for local, regional, and national utilization comparisons; and medical education and research. CPT Category I codes describe procedures and services that are consistent with contemporary medical practice. Category I codes are five-digit numeric codes. CPT Category II codes facilitate data collection for certain services and test results that contribute to positive health outcomes and quality patient care. These codes are optional and used for performance management. They are alphanumeric five-digit codes with the alpha character F in the last position. CPT Category III codes represent emerging technologies. They are alphanumeric five-digit codes with the alpha character T in the last position. The CPT Editorial Panel, appointed by the AMA Board of Trustees, is responsible for maintaining and updating the CPT code set. Purpose The AMA makes annual updates to the CPT code set, effective January 1. These updates include deleted codes, revised codes, and new codes. It’s important for providers to understand the code changes and the impact those changes will have to systems, workflow, reimbursement, and RVUs. This document is meant to assist you with this by providing a summary of the changes; a detailed breakdown of this year’s CPT changes by specialty, and HCPCS Updates for your reference.